{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:59Z","timestamp":1792194959939,"version":"4.4.0"},"reference-count":238,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2024.5669","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:35:30Z","timestamp":1720510530000},"source":"Crossref","is-referenced-by-count":17,"title":["mRNA vaccine development and applications: A special focus on tumors (Review)"],"prefix":"10.3892","volume":"65","author":[{"given":"Bangjie","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Yang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enba","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozheng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui 237008, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui 237008, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"key20240807090247_b1-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.20892\/j.issn.2095-3941.2022.0231","article-title":"Current cancer burden in China: Epidemiology, etiology, and prevention","volume":"19","author":"Maomao","year":"2022","journal-title":"Cancer Biol Med"},{"key":"key20240807090247_b2-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and cure: A critical analysis","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J Cancer"},{"key":"key20240807090247_b3-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"key20240807090247_b4-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"key20240807090247_b5-ijo-65-02-05669","first-page":"412","article-title":"Smoking tobacco and cancer risk","volume":"146","author":"Scherubl","year":"2021","journal-title":"Dtsch Med Wochenschr"},{"key":"key20240807090247_b6-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e46632","DOI":"10.15252\/embr.201846632","article-title":"Bacterial infections and cancer","volume":"19","author":"van Elsland","year":"2018","journal-title":"EMBO Rep"},{"key":"key20240807090247_b7-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","article-title":"An introduction to virus infections and human cancer","volume":"217","author":"Schiller","year":"2021","journal-title":"Recent Results Cancer Res"},{"key":"key20240807090247_b8-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"115328","DOI":"10.1016\/j.envpol.2020.115328","article-title":"Air pollution exposure and bladder, kidney and urinary tract cancer risk: A systematic review","volume":"267","author":"Zare Sakhvidi","year":"2020","journal-title":"Environ Pollut"},{"key":"key20240807090247_b9-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-023-00449-w","article-title":"Advances of mRNA vaccine in tumor: A maze of opportunities and challenges","volume":"11","author":"Yuan","year":"2023","journal-title":"Biomark Res"},{"key":"key20240807090247_b10-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA Vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20240807090247_b11-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"887125","DOI":"10.3389\/fimmu.2022.887125","article-title":"mRNA Vaccines: The dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b12-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"key20240807090247_b13-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20240807090247_b14-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"key20240807090247_b15-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"key20240807090247_b16-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: Traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol Biol Rep"},{"key":"key20240807090247_b17-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"key20240807090247_b18-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"key20240807090247_b19-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: Current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"key20240807090247_b20-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20240807090247_b21-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: Platforms and current developments","volume":"30","author":"Szabo","year":"2022","journal-title":"Mol Ther"},{"key":"key20240807090247_b22-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"key20240807090247_b23-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4949 Pt 1","key":"key20240807090247_b24-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"key20240807090247_b25-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"key20240807090247_b26-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"key20240807090247_b27-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J Exp Med"},{"key":"key20240807090247_b28-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1089\/10430349950016762","article-title":"RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization","volume":"10","author":"Zhou","year":"1999","journal-title":"Hum Gene Ther"},{"key":"key20240807090247_b29-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"mRNA vaccine: A potential therapeutic strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b30-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and Challenges in the Delivery of mRNA-based Vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"key20240807090247_b31-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e0424022","DOI":"10.1128\/spectrum.04240-22","article-title":"mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19","volume":"11","author":"Kackos","year":"2023","journal-title":"Microbiol Spectr"},{"key":"key20240807090247_b32-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","article-title":"mRNA vaccines for COVID-19: What, why and how","volume":"17","author":"Park","year":"2021","journal-title":"Int J Biol Sci"},{"key":"key20240807090247_b33-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"bbad001","DOI":"10.1093\/bib\/bbad001","article-title":"Integrated mRNA sequence optimization using deep learning","volume":"24","author":"Gong","year":"2023","journal-title":"Brief Bioinform"},{"key":"key20240807090247_b34-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key20240807090247_b35-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1039\/D0BM01947J","article-title":"Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery","volume":"9","author":"Herrera","year":"2021","journal-title":"Biomater Sci"},{"key":"key20240807090247_b36-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann Hematol"},{"key":"key20240807090247_b37-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics-developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"key20240807090247_b38-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.smim.2023.101729","article-title":"Pathways of MHC I cross-presentation of exogenous antigens","volume":"66","author":"Cruz","year":"2023","journal-title":"Semin Immunol"},{"key":"key20240807090247_b39-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"key20240807090247_b40-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/ijms21186582","article-title":"mRNA Vaccine Era-Mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240807090247_b41-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to 'potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases'","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin Immunol"},{"key":"key20240807090247_b42-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41580-021-00430-1","article-title":"Cellular origins of dsRNA, their recognition and consequences","volume":"23","author":"Chen","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20240807090247_b43-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20240807090247_b44-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1881268","DOI":"10.1080\/2162402X.2021.1881268","article-title":"An experimental model of anti-PD-1 resistance exhibits activation of TGF\u03b2 and Notch pathways and is sensitive to local mRNA immunotherapy","volume":"10","author":"Bernardo","year":"2021","journal-title":"Oncoimmunology"},{"key":"key20240807090247_b45-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2307187","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"key20240807090247_b46-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1089\/crispr.2019.0052","article-title":"The daunting economics of therapeutic genome editing","volume":"2","author":"Wilson","year":"2019","journal-title":"CRISPR J"},{"key":"key20240807090247_b47-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nbt0315-217","article-title":"$1-million price tag set for Glybera gene therapy","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"key":"key20240807090247_b48-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"key20240807090247_b49-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b50-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus Disease (COVID-19): Current status and prospects for drug and vaccine development","volume":"52","author":"Ita","year":"2021","journal-title":"Arch Med Res"},{"key":"key20240807090247_b51-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.4161\/onci.20926","article-title":"Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy","volume":"1","author":"Van Nuffel","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20240807090247_b52-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","article-title":"Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"key20240807090247_b53-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"589959","DOI":"10.3389\/fchem.2020.589959","article-title":"Advances in lipid nanoparticles for mRNA-Based cancer immunotherapy","volume":"8","author":"Guevara","year":"2020","journal-title":"Front Chem"},{"key":"key20240807090247_b54-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","article-title":"Type I Interferons Modulate CD8(+) T Cell Immunity to mRNA Vaccines","volume":"23","author":"De Beuckelaer","year":"2017","journal-title":"Trends Mol Med"},{"key":"key20240807090247_b55-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ajps.2022.05.003","article-title":"mRNA vaccines: Past, present, future","volume":"17","author":"Karam","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"key20240807090247_b56-ijo-65-02-05669","first-page":"358","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhao","year":"2020","journal-title":"Bioact Mater"},{"key":"key20240807090247_b57-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e0006108","DOI":"10.1371\/journal.pntd.0006108","article-title":"A thermostable messenger RNA based vaccine against rabies","volume":"11","author":"Stitz","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"key20240807090247_b58-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat Biotechnol"},{"key":"key20240807090247_b59-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"key20240807090247_b60-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"key20240807090247_b61-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-021-01339-1","article-title":"Clinical and immunological effects of mRNA vaccines in malignant diseases","volume":"20","author":"Heine","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b62-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"key":"key20240807090247_b63-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41565-022-01146-9","article-title":"Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery","volume":"17","author":"Dobrowolski","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"key20240807090247_b64-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41434-023-00391-4","article-title":"Terminal hairpins improve protein expression in IRES-initiated mRNA in the absence of a cap and polyadenylated tail","volume":"30","author":"Solodushko","year":"2023","journal-title":"Gene Ther"},{"key":"key20240807090247_b65-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: Advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b66-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"key20240807090247_b67-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"key20240807090247_b68-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J Control Release"},{"key":"key20240807090247_b69-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl Res"},{"key":"key20240807090247_b70-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"key20240807090247_b71-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fernandez","year":"2020","journal-title":"Trends Mol Med"},{"key":"key20240807090247_b72-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"126934","DOI":"10.1016\/j.bmcl.2019.126934","article-title":"Purification of poly-dA oligonucleotides and mRNA-protein fusions with dT(25)-OAS resin","volume":"30","author":"Engel","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"key20240807090247_b73-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"15231","DOI":"10.1021\/acsnano.2c12584","article-title":"The mRNA Vaccine Revolution: COVID-19 has launched the future of vaccinology","volume":"17","author":"Ye","year":"2023","journal-title":"ACS Nano"},{"key":"key20240807090247_b74-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","article-title":"An overview of rational design of mRNA-based therapeutics and vaccines","volume":"16","author":"To","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"key20240807090247_b75-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.gt.3300930","article-title":"Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA","volume":"6","author":"Kariko","year":"1999","journal-title":"Gene Ther"},{"key":"key20240807090247_b76-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/2051013613508729","article-title":"A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs","volume":"2","author":"Kallen","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"key20240807090247_b77-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"key20240807090247_b78-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat Commun"},{"key":"key20240807090247_b79-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: Biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key20240807090247_b80-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/wrna.15","article-title":"Regulation of mRNA decapping","volume":"1","author":"Li","year":"2010","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"key20240807090247_b81-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240807090247_b82-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14760584.2023.2232450","article-title":"Emergence of mRNA vaccines in the management of cancer","volume":"22","author":"Mohamad Razif","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"key20240807090247_b83-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol Cell Toxicol"},{"key":"key20240807090247_b84-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1021\/acschembio.0c00864","article-title":"Structural Insights into the interaction of clinically relevant phosphorothioate mRNA Cap Analogs with translation initiation factor 4E Reveal Stabilization via Electrostatic Thio-Effect","volume":"16","author":"Warminski","year":"2021","journal-title":"ACS Chem Biol"},{"key":"key20240807090247_b85-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/gt.2010.52","article-title":"Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo","volume":"17","author":"Kuhn","year":"2010","journal-title":"Gene Ther"},{"key":"key20240807090247_b86-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1261\/rna.701307","article-title":"Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells","volume":"13","author":"Grudzien-Nogalska","year":"2007","journal-title":"RNA"},{"key":"key20240807090247_b87-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.bmc.2012.01.013","article-title":"Synthesis and properties of mRNA cap analogs containing imidodiphosphate moiety-fairly mimicking natural cap structure, yet resistant to enzymatic hydrolysis","volume":"20","author":"Rydzik","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"key20240807090247_b88-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap((R)) Analog by In Vitro Transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr Protoc"},{"key":"key20240807090247_b89-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12015-018-9805-1","article-title":"Optimization of Synthetic mRNA for highly efficient translation and its application in the generation of endothelial and hematopoietic cells from human and primate pluripotent stem cells","volume":"14","author":"Suknuntha","year":"2018","journal-title":"Stem Cell Rev Rep"},{"key":"key20240807090247_b90-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/ijms24032976","article-title":"The Functional Meaning of 5'UTR in Protein-Coding Genes","volume":"24","author":"Ryczek","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20240807090247_b91-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/mt.2010.146","article-title":"A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice","volume":"18","author":"Creusot","year":"2010","journal-title":"Mol Ther"},{"key":"key20240807090247_b92-ijo-65-02-05669","first-page":"756","article-title":"Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA","volume":"15","author":"Asrani","year":"2018","journal-title":"RNA Biol"},{"key":"key20240807090247_b93-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"679344","DOI":"10.3389\/fimmu.2021.679344","article-title":"From COVID-19 to Cancer mRNA Vaccines: Moving from bench to clinic in the vaccine landscape","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front Immunol"},{"key":"key20240807090247_b94-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"801915","DOI":"10.3389\/fimmu.2022.801915","article-title":"Are There Hidden Genes in DNA\/RNA Vaccines?","volume":"13","author":"Beaudoin","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b95-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","article-title":"Codon bias and heterologous protein expression","volume":"22","author":"Gustafsson","year":"2004","journal-title":"Trends Biotechnol"},{"key":"key20240807090247_b96-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","article-title":"Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression","volume":"23","author":"Passmore","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20240807090247_b97-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nsmb.3499","article-title":"Short poly(A) tails are a conserved feature of highly expressed genes","volume":"24","author":"Lima","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"key20240807090247_b98-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"794528","DOI":"10.1155\/2015\/794528","article-title":"RNA-Based Vaccines in Cancer Immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J Immunol Res"},{"key":"key20240807090247_b99-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","article-title":"COVID-19 vaccines: The status and perspectives in delivery points of view","volume":"170","author":"Chung","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"key20240807090247_b100-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"key20240807090247_b101-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20240807090247_b102-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/vaccines9070692","article-title":"Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide","volume":"9","author":"Franzoni","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b103-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-023-01479-4","article-title":"Incorporation of a Toll-like receptor 2\/6 agonist potentiates mRNA vaccines against cancer and infectious diseases","volume":"8","author":"Gu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20240807090247_b104-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1016\/j.vaccine.2012.04.060","article-title":"RNA-based vaccines","volume":"30","author":"Ulmer","year":"2012","journal-title":"Vaccine"},{"key":"key20240807090247_b105-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/vaccines2040735","article-title":"Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles","volume":"2","author":"McCullough","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b106-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b107-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b108-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: Self-adjuvanted RNActive((R)) vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key20240807090247_b109-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"key":"key20240807090247_b110-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/vaccines7040209","article-title":"Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix","volume":"7","author":"Jong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b111-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e1008795","DOI":"10.1371\/journal.ppat.1008795","article-title":"An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection","volume":"16","author":"Egan","year":"2020","journal-title":"PLoS Pathog"},{"key":"key20240807090247_b112-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e02482","DOI":"10.1128\/JVI.02482-20","article-title":"A Dengue Virus Serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"key20240807090247_b113-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/vaccines9020148","article-title":"mRNA Vaccines against Flaviviruses","volume":"9","author":"Wollner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b114-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e28572","DOI":"10.1002\/jmv.28572","article-title":"mRNA vaccines: The future of prevention of viral infections?","volume":"95","author":"Rzymski","year":"2023","journal-title":"J Med Virol"},{"key":"key20240807090247_b115-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"key20240807090247_b116-ijo-65-02-05669","first-page":"e932915","article-title":"Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"key":"key20240807090247_b117-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMe2035557","article-title":"A new vaccine to battle covid-19","volume":"384","author":"Haynes","year":"2021","journal-title":"N Engl J Med"},{"key":"key20240807090247_b118-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.123.321878","article-title":"COVID-19, myocarditis and pericarditis","volume":"132","author":"Fairweather","year":"2023","journal-title":"Circ Res"},{"key":"key20240807090247_b119-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"key20240807090247_b120-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"884862","DOI":"10.3389\/fimmu.2022.884862","article-title":"Oral mRNA Vaccines Against Infectious Diseases-A Bacterial Perspective (Invited)","volume":"13","author":"Jawalagatti","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b121-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b122-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b123-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s12094-023-03108-6","article-title":"Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development","volume":"25","author":"Wang","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"key20240807090247_b124-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/bloodadvances.2021005941","article-title":"Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant","volume":"6","author":"Chung","year":"2022","journal-title":"Blood Adv"},{"key":"key20240807090247_b125-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/vaccines10081168","article-title":"Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b126-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"773264","DOI":"10.3389\/fimmu.2022.773264","article-title":"Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b127-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"9775","DOI":"10.7150\/thno.61677","article-title":"Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"key":"key20240807090247_b128-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","article-title":"Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b129-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"key20240807090247_b130-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/2159-8290.CD-NB2023-0028","article-title":"mRNA Vaccine Slows Melanoma Recurrence","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"key20240807090247_b131-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1097472","DOI":"10.3389\/fimmu.2023.1097472","article-title":"Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine","volume":"14","author":"Sun","year":"2023","journal-title":"Front Immunol"},{"key":"key20240807090247_b132-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.3390\/cancers15235589","article-title":"Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC","volume":"15","author":"Kiousi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20240807090247_b133-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-021-01452-1","article-title":"Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine","volume":"20","author":"Zheng","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b134-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.7150\/jca.87184","article-title":"Identification of tumor antigens and immune subtypes of high-grade serous ovarian cancer for mRNA vaccine development","volume":"14","author":"Wu","year":"2023","journal-title":"J Cancer"},{"key":"key20240807090247_b135-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"112037","DOI":"10.1016\/j.intimp.2024.112037","article-title":"The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy","volume":"132","author":"Song","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"key20240807090247_b136-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.21037\/tlcr-22-388","article-title":"Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: A case report","volume":"11","author":"Sumi","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"key20240807090247_b137-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.4161\/hv.29553","article-title":"mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer","volume":"10","author":"Rausch","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key20240807090247_b138-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther"},{"key":"key20240807090247_b139-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"783527","DOI":"10.3389\/fcell.2021.783527","article-title":"Identification of Tumor Antigens and Design of mRNA vaccine for colorectal cancer based on the immune subtype","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"key20240807090247_b140-ijo-65-02-05669","first-page":"53","article-title":"Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil Med Res"},{"key":"key20240807090247_b141-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrgastro.2011.215","article-title":"The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma","volume":"9","author":"Samuel","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20240807090247_b142-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ng.3764","article-title":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","volume":"49","author":"Makohon-Moore","year":"2017","journal-title":"Nat Genet"},{"key":"key20240807090247_b143-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"key20240807090247_b144-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44178-023-00042-z","article-title":"A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer","volume":"2","author":"Kang","year":"2023","journal-title":"Holist Integr Oncol"},{"key":"key20240807090247_b145-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1002\/cam4.4846","article-title":"Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine","volume":"11","author":"Tan","year":"2022","journal-title":"Cancer Med"},{"key":"key20240807090247_b146-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10637-022-01290-y","article-title":"Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine","volume":"40","author":"Ping","year":"2022","journal-title":"Invest New Drugs"},{"key":"key20240807090247_b147-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"983000","DOI":"10.3389\/fimmu.2022.983000","article-title":"mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model","volume":"13","author":"Sittplangkoon","year":"2022","journal-title":"Front Immunol"},{"key":"key20240807090247_b148-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"973712","DOI":"10.3389\/fonc.2022.973712","article-title":"Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"key20240807090247_b149-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.3390\/cancers14205163","article-title":"Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments","volume":"14","author":"Niemi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20240807090247_b150-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett"},{"key":"key20240807090247_b151-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20240807090247_b152-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.4049\/jimmunol.168.8.3771","article-title":"Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses","volume":"168","author":"Mellor","year":"2002","journal-title":"J Immunol"},{"key":"key20240807090247_b153-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"key20240807090247_b154-ijo-65-02-05669","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"key20240807090247_b155-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","article-title":"Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b156-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3389\/fimmu.2018.01499","article-title":"Neoantigen Vaccine delivery for personalized anticancer immunotherapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"key20240807090247_b157-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2217\/nnm-2016-0275","article-title":"Translating nanoparticulate-personalized cancer vaccines into clinical applications: Case study with RNA-lipoplexes for the treatment of melanoma","volume":"11","author":"Grabbe","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"key20240807090247_b158-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/vaccines8040776","article-title":"Neo-Antigen mRNA Vaccines","volume":"8","author":"Esprit","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"key20240807090247_b159-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240807090247_b160-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"key20240807090247_b161-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/bioinformatics\/btt375","article-title":"A comparative analysis of algorithms for somatic SNV detection in cancer","volume":"29","author":"Roberts","year":"2013","journal-title":"Bioinformatics"},{"key":"key20240807090247_b162-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cas.13131","article-title":"Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing","volume":"108","author":"Karasaki","year":"2017","journal-title":"Cancer Sci"},{"key":"key20240807090247_b163-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e000094","DOI":"10.1136\/esmoopen-2016-000094","article-title":"Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls","volume":"1","author":"Horak","year":"2016","journal-title":"ESMO Open"},{"key":"key20240807090247_b164-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"key20240807090247_b165-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jcyt.2017.01.007","article-title":"Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study","volume":"19","author":"Kongsted","year":"2017","journal-title":"Cytotherapy"},{"key":"key20240807090247_b166-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcyt.2021.08.005","article-title":"Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials","volume":"24","author":"Ingels","year":"2022","journal-title":"Cytotherapy"},{"key":"key20240807090247_b167-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"key20240807090247_b168-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00262-005-0042-5","article-title":"Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2","volume":"55","author":"Steitz","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"key20240807090247_b169-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J Immunother"},{"key":"key20240807090247_b170-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"104143","DOI":"10.1016\/j.cellimm.2020.104143","article-title":"Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity","volume":"354","author":"Mai","year":"2020","journal-title":"Cell Immunol"},{"key":"key20240807090247_b171-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"key20240807090247_b172-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the Treatment of Cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"key20240807090247_b173-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/17460441.2021.1978972","article-title":"Advances in mRNA-based drug discovery in cancer immunotherapy","volume":"17","author":"Di Trani","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"key20240807090247_b174-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.bioelechem.2021.107843","article-title":"Gene electrotransfer of IL-2 and IL-12 plasmids effectively eradicated murine B16.F10 melanoma","volume":"141","author":"Komel","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"key20240807090247_b175-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+) T Cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"key20240807090247_b176-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20240807090247_b177-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci Transl Med"},{"key":"key20240807090247_b178-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u04af, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20240807090247_b179-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1021\/acs.bioconjchem.8b00443","article-title":"In Vitro Transcribed mRNA vaccines with programmable stimulation of innate immunity","volume":"29","author":"Loomis","year":"2018","journal-title":"Bioconjug Chem"},{"key":"key20240807090247_b180-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"key20240807090247_b181-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA: A novel avenue to antibody therapy?","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b182-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol Med"},{"key":"key20240807090247_b183-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"key20240807090247_b184-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20240807090247_b185-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu Rev Med"},{"key":"key20240807090247_b186-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab-mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"key20240807090247_b187-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates-an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"key":"key20240807090247_b188-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"de Miguel","year":"2016","journal-title":"Cell Death Differ"},{"key":"key20240807090247_b189-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"key20240807090247_b190-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-021-01329-3","article-title":"mRNA in cancer immunotherapy: Beyond a source of antigen","volume":"20","author":"Van Hoecke","year":"2021","journal-title":"Mol Cancer"},{"key":"key20240807090247_b191-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA Delivery for Therapeutic Anti-HER2 antibody expression in vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b192-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ymthe.2019.09.016","article-title":"Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector induces potent antitumor responses","volume":"27","author":"Ballesteros-Briones","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b193-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"key20240807090247_b194-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"e2007603","DOI":"10.1002\/adma.202007603","article-title":"mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies","volume":"33","author":"Wang","year":"2021","journal-title":"Adv Mater"},{"key":"key20240807090247_b195-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1084\/jem.119.1.151","article-title":"Serologic demonstration of dual specificity of rabbit bivalent hybrid antibody","volume":"119","author":"Fudenberg","year":"1964","journal-title":"J Exp Med"},{"key":"key20240807090247_b196-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"key20240807090247_b197-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"12383","DOI":"10.1080\/21655979.2021.2003666","article-title":"Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery","volume":"12","author":"Wu","year":"2021","journal-title":"Bioengineered"},{"key":"key20240807090247_b198-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"key20240807090247_b199-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2008.068","article-title":"Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes","volume":"20","author":"Rabinovich","year":"2009","journal-title":"Hum Gene Ther"},{"key":"key20240807090247_b200-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"key20240807090247_b201-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"key20240807090247_b202-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell Therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"key20240807090247_b203-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-42934-2_5","article-title":"mRNA cancer vaccines","volume":"209","author":"Fiedler","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"key20240807090247_b204-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.3390\/ijms21186514","article-title":"In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) therapy in hematologic and solid tumor management: A preclinical update","volume":"21","author":"Soundara Rajan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240807090247_b205-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","article-title":"High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation","volume":"13","author":"Zhao","year":"2006","journal-title":"Mol Ther"},{"key":"key20240807090247_b206-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s10875-009-9308-6","article-title":"Transfer of Her-2\/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR)","volume":"29","author":"Yoon","year":"2009","journal-title":"J Clin Immunol"},{"key":"key20240807090247_b207-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s00262-005-0098-2","article-title":"A new way to generate cytolytic tumor-specific T cells: Electroporation of RNA coding for a T cell receptor into T lymphocytes","volume":"55","author":"Schaft","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"key20240807090247_b208-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Boissel","year":"2009","journal-title":"Leuk Res"},{"key":"key20240807090247_b209-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"key20240807090247_b210-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/gt.2008.189","article-title":"Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer","volume":"16","author":"Birkholz","year":"2009","journal-title":"Gene Ther"},{"key":"key20240807090247_b211-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum Gene Ther"},{"key":"key20240807090247_b212-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"key":"key20240807090247_b213-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3109\/14653249.2010.542461","article-title":"Transiently redirected T cells for adoptive transfer","volume":"13","author":"Almasbak","year":"2011","journal-title":"Cytotherapy"},{"key":"key20240807090247_b214-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-0716-0146-4_7","article-title":"In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development","volume":"2086","author":"Miliotou","year":"2020","journal-title":"Methods Mol Biol"},{"key":"key20240807090247_b215-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum Gene Ther"},{"key":"key20240807090247_b216-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"key20240807090247_b217-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"key20240807090247_b218-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.clim.2008.02.001","article-title":"Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells","volume":"127","author":"Bontkes","year":"2008","journal-title":"Clin Immunol"},{"key":"key20240807090247_b219-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann Oncol"},{"key":"key20240807090247_b220-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT Phase 3 Study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20240807090247_b221-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41467-018-05979-8","article-title":"Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes","volume":"9","author":"Van Hoecke","year":"2018","journal-title":"Nat Commun"},{"key":"key20240807090247_b222-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2018.12.012","article-title":"Delivery of mRNA therapeutics for the treatment of hepatic diseases","volume":"27","author":"Trepotec","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b223-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ymthe.2019.02.019","article-title":"Recent Developments in mRNA-Based protein supplementation therapy to target lung diseases","volume":"27","author":"Sahu","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b224-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J Control Release"},{"key":"key20240807090247_b225-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-Based protein replacement therapy for the heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol Ther"},{"key":"key20240807090247_b226-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.omtn.2018.03.013","article-title":"De Novo Synthesis of elastin by exogenous delivery of synthetic modified mRNA into Skin and Elastin-Deficient Cells","volume":"11","author":"Lescan","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20240807090247_b227-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jconrel.2015.01.017","article-title":"Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles","volume":"201","author":"Baba","year":"2015","journal-title":"J Control Release"},{"key":"key20240807090247_b228-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat Biotechnol"},{"key":"key20240807090247_b229-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J Transl Med"},{"key":"key20240807090247_b230-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cac2.12511","article-title":"Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer","volume":"44","author":"Raab","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"key20240807090247_b231-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20240807090247_b232-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: Prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med"},{"key":"key20240807090247_b233-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"key20240807090247_b234-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jconrel.2023.07.007","article-title":"Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy","volume":"360","author":"Ling","year":"2023","journal-title":"J Control Release"},{"key":"key20240807090247_b235-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.reth.2019.06.007","article-title":"Biomaterial-based delivery systems of nucleic acid for regenerative research and regenerative therapy","volume":"11","author":"Jo","year":"2019","journal-title":"Regen Ther"},{"key":"key20240807090247_b236-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"key20240807090247_b237-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12943-022-01650-5","article-title":"Mesenchymal stem cell-derived exosomes in cancer therapy resistance: Recent advances and therapeutic potential","volume":"21","author":"Lin","year":"2022","journal-title":"Mol Cancer"},{"key":"key20240807090247_b238-ijo-65-02-05669","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"Ramos da Silva","year":"2023","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:04:24Z","timestamp":1723010664000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2024.5669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":238,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.3892\/ijo.2024.5669","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"article-number":"81"}}